Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors.
Livmoniplimab (250 μg; three times a week; 3 weeks; i.p.) exhibits anti-tumor activity in colon cancer mice[2].
References:
[1]. Tindall RR, et al. The TGF-β superfamily as potential therapeutic targets in pancreatic cancer. Front Oncol. 2024 Mar 4;14:1362247.
[2]. Guo J, et al. A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies. Int Immunopharmacol. 2024 Mar 30;130:111782.